Bayer/Onyx win priority review for Stivarga in GIST
This article was originally published in Scrip
Executive Summary
Bayer HealthCare and Onyx Pharmaceuticals won a six-month priority review from the US FDA for Stivarga (regorafenib) as a treatment for patients with gastrointestinal stromal tumors (GIST), the companies said, although not revealing the Prescription Drug User Fee Act action date for the indication.